I agree CH. Seen many over the years in the Ph stable from Diamond, Bioshares etc and have always taken them with reservations. This one seems to have more meat on the bone IMO. It's not so much the price valuation more the depth of coverage.
It was a good preso on CHM. GBM is a devastating disease with no good options for patients. Only 4 drugs approved to treat GBM compared to 82 for breast cancer for example. Will be great to see RAD 602 in the clinic in the near future.
GLTA
RAD media and Publications, page-39
-
- There are more pages in this discussion • 159 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.7¢ |
Change
0.001(1.92%) |
Mkt cap ! $57.58M | |||
| Open | High | Low | Value | Volume |
| 2.7¢ | 2.8¢ | 2.6¢ | $39.05K | 1.450M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 2712781 | 2.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.7¢ | 400000 | 1 |
View Market Depth
| Last trade - 15.59pm 15/10/2024 (20 minute delay) ? |
| RAD (ASX) Chart |